|
|
Volumn 13, Issue SUPPL. 2, 2013, Pages
|
|
Management of secondary immune deficiencies: What is the role of immunoglobulins?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ALKYLATING AGENT;
ANTINEOPLASTIC AGENT;
AZITHROMYCIN;
B LYMPHOCYTE ANTIBODY;
BORTEZOMIB;
CORTICOSTEROID;
COTRIMOXAZOLE;
ETANERCEPT;
FLUDARABINE;
GLUCOCORTICOID;
GOLD;
IBRUTINIB;
IMMUNOGLOBULIN;
IMMUNOGLOBULIN A;
IMMUNOGLOBULIN M;
IMMUNOSUPPRESSIVE AGENT;
INFLIXIMAB;
INFLUENZA VACCINE;
MONOCLONAL ANTIBODY;
NEUTRALIZING ANTIBODY;
PENICILLAMINE;
PHENYTOIN;
PLACEBO;
PNEUMOCOCCUS VACCINE;
PURINE NUCLEOSIDE DERIVATIVE;
RITUXIMAB;
TUMOR NECROSIS FACTOR ALPHA ANTIBODY;
UNINDEXED DRUG;
USTEKINUMAB;
ADAPTIVE IMMUNITY;
AGAMMAGLOBULINEMIA;
ALLOGENEIC STEM CELL TRANSPLANTATION;
ANTIBACTERIAL ACTIVITY;
ANTIBIOTIC PROPHYLAXIS;
ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY;
ANTIINFLAMMATORY ACTIVITY;
ARTICLE;
AUTOIMMUNE DISEASE;
B CELL LYMPHOMA;
B LYMPHOCYTE;
BACTERIAL INFECTION;
BACTERIOLYSIS;
BIOLOGICAL THERAPY;
CANCER RISK;
CD4+ T LYMPHOCYTE;
CELLULAR IMMUNODEFICIENCY;
CHRONIC LYMPHATIC LEUKEMIA;
COMMON VARIABLE IMMUNODEFICIENCY;
COST EFFECTIVENESS ANALYSIS;
CYTOTOXIC T LYMPHOCYTE;
DRUG MEGADOSE;
DRUG SAFETY;
FOLLICULAR LYMPHOMA;
GUILLAIN BARRE SYNDROME;
HAEMOPHILUS INFLUENZAE;
HEALTH CARE COST;
HERPES SIMPLEX;
HERPES ZOSTER;
HUMAN;
HUMORAL IMMUNE DEFICIENCY;
IDIOPATHIC THROMBOCYTOPENIC PURPURA;
IMMUNE DEFICIENCY;
IMMUNOGLOBULIN DEFICIENCY;
INFECTION;
INFECTION RISK;
INFECTIOUS COMPLICATION;
INFLUENZA B;
LARGE CELL LYMPHOMA;
LYMPHOCYTOPENIA;
LYMPHOMA;
LYMPHOPROLIFERATIVE DISEASE;
MACROPHAGE;
META ANALYSIS (TOPIC);
MONOCLONAL IMMUNOGLOBULINEMIA;
MUCOCUTANEOUS LYMPH NODE SYNDROME;
MULTIPLE MYELOMA;
NATURAL KILLER CELL;
NEISSERIA MENINGITIDIS;
NONHUMAN;
OPSONIZATION;
PHAGOCYTOSIS;
PNEUMOCOCCAL INFECTION;
PRIORITY JOURNAL;
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;
PSORIASIS;
QUALITY ADJUSTED LIFE YEAR;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RECOMMENDED DRUG DOSE;
RECURRENT INFECTION;
REGISTER;
RHEUMATOID ARTHRITIS;
RISK BENEFIT ANALYSIS;
SEVERE COMBINED IMMUNODEFICIENCY;
STREPTOCOCCUS PNEUMONIAE;
TH17 CELL;
TUBERCULOSIS;
VACCINATION;
VIRUS INFECTION;
WALDENSTROEM MACROGLOBULINEMIA;
WISKOTT ALDRICH SYNDROME;
ANIMALS;
ANTIBODIES, BLOCKING;
ANTIBODIES, MONOCLONAL, MURINE-DERIVED;
AUTOIMMUNE DISEASES;
DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;
HEMATOLOGIC NEOPLASMS;
HUMANS;
IMMUNOGLOBULINS, INTRAVENOUS;
IMMUNOLOGIC DEFICIENCY SYNDROMES;
IMMUNOSUPPRESSION;
PRACTICE GUIDELINES AS TOPIC;
RISK ASSESSMENT;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 84880964754
PISSN: 15284050
EISSN: 14736322
Source Type: Journal
DOI: 10.1097/01.all.0000433132.16436.b5 Document Type: Article |
|
Times cited : (17)
|
|
References (0)
|